The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | Recent updates from the PROMISE study
Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, shares some updates from the PROMISE study (NCT03689595), which is screening high-risk individuals for precursor conditions including monoclonal gammopathy of undetermined significance (MGUS) and monoclonal gammopathy of indeterminate potential (MGIP). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
